



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/735,030

12/12/2003

Vahid C. Saadat

USGINZ02513

3503

40518

7590

07/21/2008

LEVINE BAGADE HAN LLP

2483 EAST BAYSHORE ROAD, SUITE 100

PALO ALTO, CA 94303

EXAMINER

LANG, AMY T

ART UNIT

PAPER NUMBER

3731

MAIL DATE

DELIVERY MODE

07/21/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/735,030	Applicant(s) SAADAT ET AL.	
	Examiner AMY T. LANG	Art Unit 3731	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 May 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 26-30,32-35 and 41-49 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 26-30,32-35 and 41-49 is/are rejected.
- 7) ☐ Claim(s) 40 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/14/2008 has been entered.

Claim Objections

Claim 40 is dependent upon a cancelled claim(s) and thus is considered incomplete. As such, this claim has not been further treated on the merits thereof. See MPEP 608.01(n)

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. **Claim 33** recites the limitation "the second tissue contact point" in line 3. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

Art Unit: 3731

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. **Claims 45-49** are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. (US 2002/0111534 A1).

With regard to **claim 45**, Suzuki et al. (hereinafter Suzuki) discloses an apparatus for performing a medical procedure within a hollow body organ (see entire document). The device comprises an overtube (84) and a first catheter (14) inserted through the overtube (Figures 1 and 3; [0038]; [0039]). It is the examiner's position that a user is able to manually steer the distal end of the overtube so that the overtube comprises a steerable distal region. As shown in Figures 1 and 12, the first catheter comprises a flexible tube and a distal tissue engaging assembly with jaws (17a, 17b) ([0039]). The tissue engaging assembly grabs a patient's tissue to form a first tissue contact point (Figure 13).

Suzuki further discloses a flexible delivery catheter (42) comprising an internal lumen through which a needle (44) is inserted ([0044]; Figure 8). Initially, the flexible delivery catheter is inserted into the patient parallel to the first catheter, a direction that is aligned with a longitudinal axis of the proximal portion of the flexible delivery catheter ([0054]). A distal portion of the flexible delivery catheter is then bent toward the first tissue contact point ([0054]; Figure 17). It is the examiner's position that the bending produces a bent catheter that is generally transverse to the longitudinal axis of the proximal portion of the catheter. The needle is then slidably extended out of the distal end of the flexible delivery catheter and through the tissue ([0055]; Figure 17). Therefore, the needle, which was previously retained within bending section, now extends from a distal end of the bending section of the flexible delivery catheter.

If applicant were to argue that the bending of the flexible delivery catheter does not produce a bend that is generally transverse to the longitudinal axis, is the examiner position that the delivery catheter of Suzuki is adapted to bend substantially ninety degrees. This would allow the needle to produce a clean cut while traversing through the tissue.

Once the needle is deployed through the tissue, as shown in Figure 17, a suture (46) on suture retaining device (50) is utilized to secure a tissue fold produced at the first tissue contact point ([0058]). Therefore, the flexible delivery catheter and suture retaining device work together to deliver an anchor, suture (36), and secure a tissue fold and therefore together overlap the instantly claimed anchor delivery assembly.

With regard to **claims 47 and 48**, Suzuki further discloses endoscope (2 or 6) movably disposed within the overtube ([0038]).

With regard to **claims 46 and 49**, the anchor, suture (46) is configured to be delivered through the needle (44) since the suture is inserted in the needle ([0058]).

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

Art Unit: 3731

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

9. **Claims 26-30, 32-35, and 41-44** are rejected under 35 U.S.C. 103(a) as being unpatentable over Suzuki et al. (US 2002/0111534 A1) in view of Jaffe (US 2002/0161281 A1).

With regard to **claim 26**, as discussed in paragraph 6 above and incorporated here by reference, Suzuki discloses an apparatus for performing a medical procedure comprising an overtube, a first catheter with a distal tissue engaging assembly, and an anchor delivery assembly.

However, Suzuki does not specifically disclose the guide tube as having a flexible state and a rigid state.

Jaffe discloses an overtube, guide tube (14), designed to facilitate insertion of an endoscope through a tortuous pathway ([0002]). The guide tube is slideably disposed over the catheter and comprises a flexible and rigid state (Figure 1; [0028]; [0037]; [0038]). As shown in Figure 3, tensioning elements (30) transition the overtube between the flexible and rigid states ([0041]). Therefore, tensioning elements (30) clearly overlap the instantly claimed mechanism. It is the examiner's position that the tensioning elements are configured to be manipulated from outside a patient's body.


Since the overtube of Jaffe advantageously facilitates insertion of an endoscope through an internal passageway, it would have been obvious to one of ordinary skill at the time of the invention for Suzuki to utilize the overtube of Jaffe.

With regard to **claims 27-29**, Jaffe teaches wherein tensioning elements (30) are placed circumferentially about the overtube to control the transition from a flexible to rigid state or vice versa. The tensioning elements may be manipulated individually, so that only one portion of the overtube is transitioned ([0041]). For instance, as shown in Figure 3 of Jaffe, when only tensioning element 30B is manipulated, only that side of the overtube would transition from a flexible to a rigid state or vice versa. The side of the overtube that tensioning element 30D runs would not transition, so that only one section of the overtube remains in a flexible or rigid state while another section is manipulated and transitioned to the opposite state.

With regard to **claim 30**, Jaffe further discloses tip (26), which is steerable (Figure 1).

With regard to **claim 32**, as shown in Figure 17 of Suzuki, the needle contacts the tissue at a location proximal of the first tissue contact point.

With regard to **claim 33**, it is also the examiner's position that each jaw member (17a, 17b) of Suzuki touches the tissue to form a first and second tissue contact point. As shown in Figure 17, the first tissue contact point is proximal of the second tissue contact point. Slider handle (23) manipulates the jaw members and therefore overlaps the instantly claimed tissue approximation device.



With regard to **claims 34 and 35**, Suzuki merely discloses two catheters inserted within an overtube (Figure 1). Therefore, it is the examiner's position that it would have been obvious at the time of the invention to flip the device so that the first catheter lies above the flexible delivery catheter. This entry angle would be advantageous while attempting to access various anatomical parts. Therefore, the tissue grabbing assembly would contact the tissue to form first and third contact points. The needle would produce a second tissue contact point and the first tissue contact point would be proximal of the third tissue contact point. Additionally, all three tissue contact points would be linearly displaced.

With regard to **claims 41-44**, the apparatus disclosed by Suzuki in view of Jaffe is configured to engage mucosa, muscularis, or serosa.

Response to Arguments

10. Applicant's arguments, filed 05/14/2008, with respect to the Double Patenting Rejection and the rejection of Laufer have been fully considered and are persuasive. The rejections have been withdrawn.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY T. LANG whose telephone number is (571)272-9057. The examiner can normally be reached on M-F 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Todd Manahan can be reached on 571-272-4713. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

Art Unit: 3731

like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

07/14/2008

/Amy T Lang/

Examiner, Art Unit 3731

/Todd E Manahan/

Supervisory Patent Examiner, Art Unit 3731